The forum offers physicians from around the world an opportunity to share with their colleagues varying aspects of
Select presentations from this year's program include the following:
- Why I Made the Jump to Fovea-Friendly MicroPulse Laser Therapy for the Macula, presented by Dr.
Jeanne Rosenthal , Surgeon Director and Senior Attending Surgeon at theNew York Eye and Ear Infirmary ofMount Sinai ; and Dr.Julia Shulman , Director of Clinical Research and Associate Residency Program Director atJamaica Hospital Medical Center in Queens and Clinical Instructor of Ophthalmology in the Pediatric Retina Division atNew York Eye and Ear Infirmary ofMount Sinai .Sunday, October 19 at11:30 AM - Rethinking Our Regimen for Retinal Disease Management, presented by
Ahad Mahootchi , MD, Medical Director ofThe Eye Clinic of Florida .Saturday, October 18 at1:00 PM - Laser Treatment Alternatives in Glaucoma, presented by
Iqbal (Ike) Ahmed , MD, FRCSC, Assistant Professor and Research Fellowship Director,Department of Ophthalmology ,University of Toronto .Sunday, October 19 at2:30 PM
For the complete
About MicroPulse
MicroPulse laser therapy is a tissue-sparing solution for the treatment of retinal diseases and glaucoma. With MicroPulse, a continuous-wave laser beam is chopped into a train of tiny, repetitive, low energy pulses separated by a brief rest period which allows the tissue to cool between laser pulses. MicroPulse laser therapy also can be used in conjunction with drug therapy, allowing complete and optimized management of retinal diseases and glaucoma without laser-induced damage.
About
Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning the effectiveness and safety of Company products, the Company's future financial performance, the Company's strategic plans and objectives, and trends in treatment and product usage. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in the Company's Annual Report on Form 10-K for the fiscal year ended
Logo - http://photos.prnewswire.com/prnh/20141001/149809
SOURCE
IRIDEX: Jim Mackaness, CFO & COO, 650-940 4700; Investor Relations: Matt Clawson, Pure Communications, 949-370-8500, matt@purecommunicationsinc.com